首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3186篇
  免费   304篇
  国内免费   210篇
林业   183篇
农学   172篇
基础科学   24篇
  108篇
综合类   956篇
农作物   141篇
水产渔业   295篇
畜牧兽医   1243篇
园艺   513篇
植物保护   65篇
  2024年   6篇
  2023年   58篇
  2022年   104篇
  2021年   137篇
  2020年   145篇
  2019年   170篇
  2018年   104篇
  2017年   179篇
  2016年   184篇
  2015年   146篇
  2014年   173篇
  2013年   230篇
  2012年   248篇
  2011年   217篇
  2010年   162篇
  2009年   143篇
  2008年   165篇
  2007年   159篇
  2006年   114篇
  2005年   99篇
  2004年   86篇
  2003年   78篇
  2002年   73篇
  2001年   66篇
  2000年   61篇
  1999年   35篇
  1998年   29篇
  1997年   43篇
  1996年   32篇
  1995年   32篇
  1994年   31篇
  1993年   25篇
  1992年   28篇
  1991年   26篇
  1990年   26篇
  1989年   24篇
  1988年   13篇
  1987年   10篇
  1986年   9篇
  1985年   6篇
  1984年   3篇
  1983年   3篇
  1980年   4篇
  1979年   1篇
  1977年   1篇
  1976年   2篇
  1975年   1篇
  1974年   4篇
  1973年   1篇
  1956年   2篇
排序方式: 共有3700条查询结果,搜索用时 203 毫秒
61.
62.
旨在评价不同剂量伊曲康唑-环糊精制剂通过皮下注射途径对健康比格犬肝肾功能及血常规的影响。选用体重±10 kg的健康纯种比格犬32只,按试验要求随机分为4组,每组8只,建立稳定的生活制度。分别按照0.25 mg/kg、0.75 mg/kg和1.25 mg/kg剂量,皮下注射伊曲康唑制剂,3日1次,连续7次,对照组注射生理盐水。于试验过程中第0、5、10、15、19天采集相关样品,对犬临床表现、血常规指标、血液生化指标、尿常规指标及肝肾功能进行全面的评价。结果表明,给药组与对照组相比,除白细胞相关指标外,其余指标都在正常范围内。给药组在试验过程中均出现白细胞升高现象,但在试验结束后5 d内均恢复正常。因此,伊曲康唑-环糊精制剂作为犬皮下注射剂型,具有良好的安全性和耐受性,操作方便,动物依从性好,适合兽医临床应用。  相似文献   
63.
为研究不同剂量的环磷酰胺对小鼠肝肾组织及功能的损害程度,试验选取40只5周龄健康雌性昆明小鼠,随机分为5组,除对照组外,其余4组小鼠连续3 d分别腹腔注射40、80、120及160 mg/(kg·BW)环磷酰胺溶液,注射后第7天采集肝脏和肾脏组织样品及血清,制备石蜡组织切片及透射电镜切片,观察肝脏和肾脏的组织学变化,检测血清中甘胆酸(CG)、胆碱酯酶(ChE)、血清前白蛋白(PA)、总胆汁酸(TBA)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、尿素氮(BUN)、血清肌酐(SCr)、尿酸(UA)含量/活性。结果显示,环磷酰胺可引起小鼠肝肾组织病理损害,呈剂量依赖性,肝脏比肾脏更早出现损伤。石蜡切片及透射电镜切片观察结果显示,环磷酰胺对肝脏的毒性作用主要表现在肝索紊乱、肝血窦扩张、微胆管淤胆、门管区及中央静脉周围炎性细胞浸润及纤维增生、组织间出血、肝细胞出现脂肪变性及气球样变性,凋亡及坏死细胞增多。肾脏组织损伤主要表现在出血及纤维增生,肾小管上皮细胞胞浆空泡样变、线粒体损伤、核固缩,上皮细胞基底膜增厚。环磷酰胺对膀胱的损害不严重。与对照组相比,40~160 mg/(kg·BW)剂量组小鼠血清中ChE活性及PA水平,120~160 mg/(kg·BW)剂量组AST活性,80~160 mg/(kg·BW)剂量组BUN水平及80 mg/(kg·BW)剂量组UA水平均显著升高(P<0.05);其余生化指标与对照组差异不显著(P>0.05)。以上结果表明,环磷酰胺注射剂量在80~120 mg/(kg·BW)时可引起昆明小鼠肝脏和肾脏组织及细胞明显的病理损伤。该研究结果可为选择合适的环磷酰胺注射剂量用以制备动物肝脏免疫抑制模型提供试验依据。  相似文献   
64.
ObjectiveTo collect data about the current practice of recovering horses from general anesthesia and recovery personnel safety.Study designOnline survey.MethodsAn online questionnaire, including questions on general demographic data, recovery drugs, modality and characteristics of equine recovery and morbidity and mortality, was designed and distributed via e-mail to equine practitioners worldwide.ResultsPractitioners from 22 countries completed 373 questionnaires; 53% of the participants were board-certified equine surgeons, and the remainder were board-certified anesthesiologists (18%), large animal residents (8%), general practitioners (7%), large animal interns (6%), anesthesia residents (4.5%) and veterinary technicians (1.6%). Respondents were employed by academia (58%) or private practice (42%). Of the respondents employed at a university, 93% had a board-certified anesthesiologist on staff compared with 7% of respondents employed at a private practice. Most of the respondents assist horses during recovery, with 23% assisting every recovery and 44% assisting recovery in the majority of cases. Reasons for choosing to assist horses during recovery were: orthopedic procedures (57%), neurological deficits (49%), bad health (47%), history of poor recovery (44%), foals (42%), draft breeds (30%), magnetic resonance imaging (17%) and computed tomography (16%). Unacceptable recoveries were reported by 77% of participants. Commonly reported complications during recovery with any method were: orthopedic injury (66%), myopathy (54%), skin abrasion (53%) and airway obstruction (37%). The incidences of unacceptable quality of recovery (p = 0.09) or personnel injury (p = 0.56) were not different between assisted and nonassisted recoveries; however, more equine fatalities were reported for assisted recoveries (p < 0.006). Practitioners in academia reported more unacceptable recoveries (p < 0.0007) and personnel injuries (p < 0.002) compared with those in private practice.ConclusionsThe method of recovery differs among hospitals. Recovery personnel injuries associated with assisting horses during recovery are an important and previously unreported finding.  相似文献   
65.
66.
Sarcocystidae is a family of coccidian protozoa from the phylum Apicomplexa that includes Toxoplasma, Neospora, Sarcocystis, Hammondia, and Besnoitia spp. All species undergo a 2‐host sexual and asexual cycle. In the definitive host, replication is enteroepithelial, and infection is typically asymptomatic or less commonly causes mild diarrhea. Clinical disease is most frequently observed in the intermediate host, often as an aberrant infection, and is mostly associated with neurologic, muscular, or hepatic inflammation. Here, we review the literature regarding intestinal Sarcocystidae infections in dogs and cats, with emphasis on the life cycle stages and the available diagnostic assays and their limitations. We also report the diagnostic findings for an 11‐year‐old dog with acute neutrophilic hepatitis, biliary protozoa, and negative biliary culture. Although Toxoplasma and Neospora IgG titers were both high, PCR for these 2 organisms was negative for bile. The organisms were identified by 18S rDNA PCR as most consistent with Hammondia, either H heydorni or H triffittae. This is the first report of presumed Hammondia organisms being found in canine bile.  相似文献   
67.
68.
69.
70.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号